Eirik Næss-Ulseth • 1956 • Oslo • 15 roles • 15 shareholdings

This website uses cookies to enhance the user experience.

Roles

Management

Name	Role	Total operating income	Total equity	Shares
S SHARPXVIEW AS	Managing Director/CEO	1,265,000	651,338	30 % indirectly

Boards

Name	Role	Total operating income	Total equity	Shares
S SKILLING SYSTEMER AS	Chairman	664,100	10,177,439	60 % directly
C CELLMOVER AS	Board Member	4,153,400	866,623	54.12 % directly 29.41 % indirectly 24.71 %
I INVENTRON AS	Chairman	-	96,433	32.96 % indirectly
S SHARPXVIEW AS	Chairman	1,265,000	651,338	30 % indirectly
A ARCTIC PHARMA AS	Chairman	5,291,365	3,383,767	24.26 % indirectly
V VITAE EVIDENCE AS	Board Member	1,286,300	6,000,092	22.9 % directly 1.41 % indirectly 21.49 %
E EQUANOSTIC AS	Chairman	17,804,830	3,140,395	22.45 % indirectly
B BIOMOLEX AS	Chairman	2,515,404	156,837	11.88 % directly 2.4 % indirectly 9.47 %
S SPERMATECH AS	Board Member	2,715,248	1,216,525	11.21 % indirectly
C COREMINE BIL	Board Member	-	-	-
P PUBGENE AS	Chairman	11,634,488	11,626,306	-
H HECOTRON AS	Alternate Member	-	5,592,845	-
H HECOTRON INDUSTRIELL ELEKTRONIKK AS	Board Member	15,585,282	6,491,955	-
T TOBORA AS	Board Member	-	-	-

Last update: Aug 1, 2024

Related industries5

Professional, scientific and technical activities
Arts, entertainment and recreation
Information and communication
Wholesale and retail trade; repair of motor vehicles and motorcycles
Administrative and support service activities

Direct relationships5

HH
Håvard Hildeng Hauge1969
COREMINE BIL, PUBGENE AS, BIOMOLEX AS, VITAE EVIDENCE AS
BS
Bjørn Steen Skålhegg1959
ARCTIC PHARMA AS, SPERMATECH AS, TOBORA AS
GH
Gunnar Hvammen1963
ARCTIC PHARMA AS, SPERMATECH AS
EM
Espen Marcelius Gjems1978
COREMINE BIL, SPERMATECH AS
EN
Einar Nygård1962
INVENTRON AS, SHARPXVIEW AS

Shares owned by Eirik Næss-Ulseth

Name	Share class	Total operating income	Total equity	Share
S SKILLING SYSTEMER AS	Ordinære aksjer	664,100	10,177,439	60 % directly
I INVENTRON AS		0	96,433	32.96 % indirectly
S SHARPXVIEW AS		1,265,000	651,338	30 % indirectly
C CELLMOVER AS	Ordinære aksjer	4,153,400	866,623	29.41 % directly 29.41 % indirectly 24.71 %
A ARCTIC PHARMA AS		5,291,365	3,383,767	24.26 % indirectly
E EQUANOSTIC AS		17,804,830	3,140,395	22.45 % indirectly
R RHEUMATECH AS		179,900	341,910	15.58 % indirectly
S SKIPLUKKERN AS		11,395,626	1,724,414	15 % indirectly
T TRYGG NATT AS		0	19,662	11.22 % indirectly
S SPERMATECH AS		2,715,248	1,216,525	11.21 % indirectly
B BIOMOLEX AS	NO0010162266	2,515,404	156,837	2.4 % directly 2.4 % indirectly 9.47 %
V VITAE EVIDENCE AS	Ordinære aksjer	1,286,300	6,000,092	1.41 % directly 1.41 % indirectly 21.49 %
C COREMINE VITAE AS	Ordinære aksjer	2,259,385	1,763,479	1.07 % directly 1.07 % indirectly 16.2 %
A AIRTHINGS ASA		358,046,000	499,499,000	0.86 % indirectly
N NOVELDA AS	NO0010733454	15,583,472	127,323,381	0.11 % directly 0.11 % indirectly 0.66 %

Limited to direct ownership positions of 0.5% or more.

Last update: May 24, 2024